• RBC Capital sets a price target of $90 for NYSE:INSP, indicating a potential upside of approximately 10.66%.
• Baillie Gifford & Co. reduces its stake in INSP by 2.7%, selling 29,538 shares, while Texas Permanent School Fund Corp increases its holdings by 42.2%.
• INSP's stock price stands at $81.33, with a year's volatility ranging from $70.77 to $203.12 and a market capitalization of approximately $2.41 billion.

Inspire Medical Systems, Inc. (NYSE:INSP) is a company that specializes in innovative medical solutions, particularly in the field of sleep apnea treatment. The company is known for its Inspire therapy, a device that offers an alternative to traditional treatments like CPAP machines. Inspire Medical competes with other medical device companies in the sleep apnea market, striving to provide effective and user-friendly solutions.

On January 26, 2026, RBC Capital set a price target of $90 for INSP, while the stock was trading at $81.33. This suggests a potential upside of approximately 10.66%. Despite this optimistic outlook, Baillie Gifford & Co. has reduced its stake in the company by 2.7%, selling 29,538 shares. This reduction leaves them with 1,084,350 shares, valued at $80.5 million, representing about 3.67% of the company.

In contrast, other institutional investors have shown increased interest in INSP. The Texas Permanent School Fund Corp has increased its holdings by 42.2%, acquiring an additional 11,892 shares. This brings their total to 40,042 shares, valued at $5.2 million. Nordea Investment Management AB has also entered a new position, investing approximately $1.6 million during the second quarter.

The stock for INSP is currently priced at $81.33, reflecting a 2.43% increase or $1.93. Throughout the day, the stock has fluctuated between $78.17 and $81.76. Over the past year, INSP has experienced significant volatility, with a high of $203.12 and a low of $70.77. The company's market capitalization stands at approximately $2.41 billion, with a trading volume of 1,084,065 shares on the NYSE.